Literature DB >> 1829648

Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity.

S Haskill1, A A Beg, S M Tompkins, J S Morris, A D Yurochko, A Sampson-Johannes, K Mondal, P Ralph, A S Baldwin.   

Abstract

We have cloned a group of cDNAs representing mRNAs that are rapidly induced following adherence of human monocytes. One of the induced transcripts (MAD-3) encodes a protein of 317 amino acids with one domain containing five tandem repeats of the cdc10/ankyrin motif, which is 60% similar (46% identical) to the ankyrin repeat region of the precursor of NF-kappa B/KBF1 p50. The C-terminus has a putative protein kinase C phosphorylation site. In vitro translated MAD-3 protein was found to specifically inhibit the DNA-binding activity of the p50/p65 NF-kappa B complex but not that of the p50/p50 KBF1 factor or of other DNA-binding proteins. The MAD-3 cDNA encodes an I kappa B-like protein that is likely to be involved in regulation of transcriptional responses to NF-kappa B, including adhesion-dependent pathways of monocyte activation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829648     DOI: 10.1016/0092-8674(91)90022-q

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  233 in total

1.  Integrin-mediated adhesion of endothelial cells induces JAK2 and STAT5A activation: role in the control of c-fos gene expression.

Authors:  M F Brizzi; P Defilippi; A Rosso; M Venturino; G Garbarino; A Miyajima; L Silengo; G Tarone; L Pegoraro
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

Review 2.  Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha.

Authors:  R T Hay; L Vuillard; J M Desterro; M S Rodriguez
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-09-29       Impact factor: 6.237

3.  Characterization of Chlamydomonas reinhardtii zygote-specific cDNAs that encode novel proteins containing ankyrin repeats and WW domains.

Authors:  H Kuriyama; H Takano; L Suzuki; H Uchida; S Kawano; H Kuroiwa; T Kuroiwa
Journal:  Plant Physiol       Date:  1999-03       Impact factor: 8.340

4.  Interaction between hnRNPA1 and IkappaBalpha is required for maximal activation of NF-kappaB-dependent transcription.

Authors:  D C Hay; G D Kemp; C Dargemont; R T Hay
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

5.  I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity.

Authors:  S T Whiteside; J C Epinat; N R Rice; A Israël
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

6.  Tax induces nuclear translocation of NF-kappa B through dissociation of cytoplasmic complexes containing p105 or p100 but does not induce degradation of I kappa B alpha/MAD3.

Authors:  E Muñoz; G Courtois; P Veschambre; P Jalinot; A Israël
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP.

Authors:  E Spencer; J Jiang; Z J Chen
Journal:  Genes Dev       Date:  1999-02-01       Impact factor: 11.361

8.  Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination.

Authors:  D C Scherer; J A Brockman; Z Chen; T Maniatis; D W Ballard
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway.

Authors:  I Alkalay; A Yaron; A Hatzubai; A Orian; A Ciechanover; Y Ben-Neriah
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

10.  Viral induction of the human beta interferon promoter: modulation of transcription by NF-kappa B/rel proteins and interferon regulatory factors.

Authors:  E Garoufalis; I Kwan; R Lin; A Mustafa; N Pepin; A Roulston; J Lacoste; J Hiscott
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.